Minimal Residual Disease Market: Clinical Applications, Reimbursement Hurdles and Competitive Dynamics
Beyond technology, the minimal residual disease market is shaped by where MRD results are used in patient care and how providers and payers respond. Polaris Market Research values the global market at USD 2.38 billion in 2025 and projects USD 7.20 billion by 2034, at a CAGR of 13.1% from 2026 to 2034. The report names the increasing number of cancer patients, rising R&D spending and the adoption of precision medicine among the key growth drivers. This article reviews the clinical applications, adoption barriers and competitive landscape that B2B stakeholders should watch.
Leukemia MRD Testing Leads by Detection Target
Leukemia accounted for the largest share of 38.6% in 2025, owing to the high incidence of blood cancers and increasing investment in leukemia therapeutics. Demand for leukemia MRD testing is tied to case volumes: Polaris cites American Cancer Society estimates of approximately 22,760 chronic lymphocytic leukemia cases in the U.S. in 2026. The report adds that studies suggest next-generation sequencing may reduce undiscovered residual disease, enabling early care that is essential for survival in acute lymphocytic leukemia. In that setting, leukemia MRD testing supports early and accurate diagnosis.
The lymphoma segment is expected to grow at a 13.8% CAGR, with non-Hodgkin lymphoma presenting the higher opportunity because it covers numerous subtypes and involves more advanced monitoring approaches. In December 2025, Natera acquired Foresight Diagnostics, a developer of blood tests for tracking MRD, for USD 450 million.
Multiple Myeloma: MRD as a Clinical Endpoint
Multiple myeloma is expected to grow at a 12.9% CAGR during the forecast period, as it is one of the key applications of MRD testing. MRD negativity, meaning the absence of cancer cells after therapy, is increasingly used as an important indicator of treatment response and as a powerful clinical trial endpoint that can speed the study of new treatments. FDA Oncologic Drugs Advisory Committee discussions have fueled the adoption of MRD as an endpoint.
The report also points to the EMN02/HO95 multiple myeloma trial, in which rising MRD levels after autologous stem-cell transplant preceded biochemically assessed changes, making flow-MRD an early indicator of relapse ahead of conventional markers. FDA approval of MRD as a surrogate endpoint in blood cancers would further boost adoption in oncology drug development.
Precision Oncology and CAR-T Monitoring
MRD testing supports precision oncology by providing detailed information on how a patient responds to treatment. Instead of a uniform approach, medical professionals use these results to guide strategy for each patient and to tailor follow-up to individual risk levels.
MRD testing is also expected to play a major role in immunotherapy and CAR-T monitoring, showing how far cancer cells have responded to therapies designed to target them. In the ZUMA-7 trial, ctDNA profiling was used to detect MRD in relapsed or refractory large B-cell lymphoma, and MRD negativity showed high concordance with PET-based complete remission. The report says this helps validate ctDNA-based bioinformatics as a response-assessment tool. Stem cell transplant is a related use, where MRD testing helps in pre- and post-transplant stages and can inform the timing and dose of post-transplant chemotherapy.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market
MRD Testing Reimbursement and Other Adoption Barriers
Limited reimbursement policies challenge adoption. According to the report, most insurers offer limited coverage, which makes testing unaffordable for average citizens, and policies can vary by cancer type and treatment methodology. Newer technologies may also lack the supporting documentation insurers require. Insufficient MRD testing reimbursement may discourage healthcare professionals from adopting MRD testing as a first-line diagnostic tool.
Two other restraints compound the issue. Testing is high-cost because it needs sophisticated machines, skilled staff and sometimes serial testing, which can place it out of reach in low-income economies and for small hospitals and laboratories. A lack of standardized procedures also means different institutions may use different approaches, and test sensitivity can vary with the equipment used. The report expects increased standardization and improved MRD testing reimbursement to propel adoption.
End Users and Regional Dynamics
Hospitals and specialty clinics held the largest end-user share, at 50.6% in 2025, supported by a large base of cancer patients, specialized professionals and treatment infrastructure. Laboratory centers are expected to grow at a 14.7% CAGR as hospitals outsource specialized testing to labs with advanced technology and greater scalability. North America led with a 45.7% share in 2025, Asia Pacific is expected to grow at a 15.2% CAGR, and India is expected to grow at 16.8%.
Competitive Landscape and Key Players
Key players named by Polaris Market Research include Natera, Adaptive Biotechnologies, Guardant Health, Roche, QIAGEN, Sysmex and NeoGenomics, with Bio-Rad Laboratories, Invivoscribe, Quest Diagnostics and Mission Bio also listed among major players. In January 2025, Adaptive Biotechnologies and NeoGenomics announced a partnership to improve MRD monitoring for blood cancer patients, and in May 2026 Illumina launched a distributed whole-genome sequencing solution for MRD research. The report describes strategic partnerships with hospitals, pharmaceutical companies and research institutions as an important part of competition.
Conclusion
Clinical use of MRD testing is broadening from leukemia, the largest detection-target segment, into lymphoma, myeloma and solid tumors. The minimal residual disease market is expected to benefit from precision medicine, clinical trial use and technology advances, while cost, standardization and reimbursement remain the main hurdles. How well vendors and payers address these barriers will shape adoption.
More Trending Latest Reports By Polaris Market Research:
Revenue Cycle Management Market
Outsourced Semiconductor Assembly and Test (OSAT) Market